FIELD: pharmacy.
SUBSTANCE: compounds are intended for application in treatment of diseases and disorders such as cognitive diseases and disorders, cognitive activity and analgesia, particularly for neuropathic pain relief and/or reduction. .
EFFECT: enhanced efficiency of NMDA receptor activity modulation.
12 cl, 16 dwg, 4 tbl, 24 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMBINATION OF ATYPICAL ANTIPSYCHOTIC AND NMDA MODULATOR FOR TREATMENT OF SCHIZOPHRENIA, BIPOLAR DISORDER, COGNITIVE DISORDER, AND CLINICAL DEPRESSION | 2016 |
|
RU2802972C2 |
ANTIVIRAL COMPOUNDS | 2010 |
|
RU2541571C2 |
TRITERPENE DERIVATIVES OF LUPEOL TYPE AS ANTIVIRAL PREPARATIONS | 2010 |
|
RU2561604C2 |
3-AMINOPYRROLIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | 2003 |
|
RU2355679C2 |
CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS FOR APPLICATION | 2012 |
|
RU2638552C2 |
MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
Authors
Dates
2017-05-31—Published
2012-10-24—Filed